Health & Fitness
Health and Fitness
Health and Fitness
Thu, October 20, 2011
[ Thu, Oct 20th 2011
] - Market Wire
[ Thu, Oct 20th 2011
] - Market Wire
[ Thu, Oct 20th 2011
] - Market Wire
[ Thu, Oct 20th 2011
] - Market Wire
[ Thu, Oct 20th 2011
] - Market Wire
Wed, October 19, 2011
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
[ Wed, Oct 19th 2011
] - Market Wire
Los datos sobre el uso temprano y los beneficios a largo plazo de TYSABRI han sido presentados en el 5 congreso trienal conjun
WESTON, Massachussets & DUBLIN--([ BUSINESS WIRE ])--[ Biogen Idec ] (NASDAQ: BIIB) y [ Elan Corporation, plc ](NYSE: ELN) han anunciado las 28 presentaciones de la empresa sobre TYSABRI? (natalizumab) durante el 5? congreso trienal conjunto de los comit?s europeos y americanos para el tratamiento e investigaci?n de la esclerosis m?ltiple (ECTRIMS y ACTRIMS), celebrado en ?msterdam (Holanda).
El comunicado en el idioma original, es la versi?n oficial y autorizada del mismo. La traducci?n es solamente un medio de ayuda y?deber? ser?comparada con el texto en idioma original, que es la ?nica versi?n del texto que tendr? validez legal.
Contributing Sources
